Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans ...

OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting ...

Briquilimab was well tolerated in the study. No SAEs or AEs grade 3 were reported. Furthermore, there were no reported AEs related to hair or skin color changes, hypersensitivity, or anemia. Mild ...

Vitiligo is a disease that causes areas of the skin to lose color, with non-segmental vitiligo ... company focused on developing host-directed therapeutics for immuno-inflammatory diseases ...

No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6 th, 2025, including 180mg Q8W cohort Company to host conference call ...

Despite a challenging biotech market, Lineage Cell Therapeutics Inc (LCTX) strengthens partnerships and maintains a strong ...

Vistagen Therapeutics Inc (VTGN) reports increased R&D expenses amid promising clinical advancements and strong financial ...

Among the newer initiatives was developing the lab of the future; next-gen biology; AI and sustainability. The new facility ...

Corcept could be significantly undervalued based on long term potential growth and science-based innovation. Find out why ...

25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ ... greater than 10% of barzolvolimab treated patients were hair color changes, neutropenia, urticaria, skin hypopigmentation ...

Perspective Therapeutics has done well to advance several radiotherapeutics to treat various types of cancers. Again, I think it was important to bring up VMT-01 for the targeting of patients with ...